Arcutis Biotherapeutics Inc., a commercial-stage biopharmaceutical company, has announced that David Topper, Arcutis’ chief financial officer (CFO) is retiring from the Company. Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Topper will continue to serve as CFO until the filing of the Company’s first quarter 10-Q and will provide transition support through his departure on May 15, 2025.

“On behalf of the Board of Directors and our entire leadership team, I would like to extend our gratitude to David for his contributions to Arcutis, both during his time as our CFO and prior to that, as a strategic advisor to the Company,” said Frank Watanabe, Arcutis president and CEO.

“I am delighted to be able to announce that Latha will succeed David as CFO,” Watanabe continued. “We are confident that with her deep understanding of our business, broad professional experience, and strong relationships across our entire organization and industry, she will be able to build on the strong foundation and lead our financial operations effectively.”

Experience

Vairavan has over 20 years of finance and accounting professional experience in the biotech industry. She joined Arcutis in 2020 to lead financial planning and analysis, and later served as vice president of finance and investor relations before assuming her current role as vice president, finance and corporate controller, where she has been responsible for overseeing daily accounting operations, ensuring compliance with financial, accounting, and income tax regulations, managing all investor relations activities, and overseeing financial planning and analysis.

Previously, Vairavan was at Amgen for 12 years, where she held various roles of increasing responsibility within the finance organization, culminating as finance director for U.S. value and access. She started her career as a financial consultant working for KPMG and Arthur Andersen. She holds a BS in Business Administration, Finance, from the University of Southern California, and is a licensed CPA in California.

“I am excited to take on the role as CFO as we launch and further commercialize ZORYVE in multiple inflammatory skin conditions and build upon our strong financial position,” said Vairavan. “Having been part of the team for several years, I’ve witnessed firsthand the incredible momentum we’re building, and I look forward to helping drive our continued growth and financial strength.”